Our lab aims to develop research pipelines to identify predictive factors that have unique power to predict minimal toxicities and maximal treatment efficacies for anti-cancer therapies, especially focuses on translating our discoveries into clinic.We are also interest in functional factors or pathways that mediate crosstalk between immune related toxicities and immune response in patients treated by immunotherapies. We are dedicated to maximize clinical benefits of cancer patients by collaborating with clinicians and biologists.

Current key researches:

Development of predictive models for lower anti-cancer therapy toxicity risks and higher treatment efficacies.

Characterization of unique molecular features associated with immune related toxicities.

Exploring potential anti-cancer therapeutic targets with low toxicity risks based on multi-dimensional big data.